Do Cardiac Biomarkers NT-proBNP and hsTnT Predict Microvascular Events in Patients With Type 2 Diabetes? Results From the ADVANCE Trial
暂无分享,去创建一个
M. Woodward | G. Hillis | N. Sattar | B. Williams | N. Poulter | M. Marre | J. Chalmers | A. Patel | S. Harrap | P. Welsh | Qiang Li | L. Ryan
[1] A. Sjølie,et al. N-terminal pro brain natriuretic peptide reflects long-term complications in type 1 diabetes , 2010, Scandinavian journal of clinical and laboratory investigation.
[2] F. Gueyffier,et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials , 2011, BMJ : British Medical Journal.
[3] Grant D. Huang,et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. , 2011, Journal of diabetes and its complications.
[4] J. Chalmers,et al. Importance of Blood Pressure Lowering in Type 2 Diabetes: Focus on ADVANCE , 2010, Journal of cardiovascular pharmacology.
[5] A. Jaffe,et al. Practice Guidelines : Use of Cardiac Troponin and B-Type Natriuretic Peptide or N-Terminal proB-Type Natriuretic Peptide for Etiologies Other than Acute Coronary Syndromes and Heart Failure , 2007 .
[6] A. Jaffe,et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. , 2007, Clinical chemistry.
[7] Yang Qiu,et al. US Renal Data System 2010 Annual Data Report. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[8] V. Gudnason,et al. N-terminal pro-brain natriuretic Peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without pre-existing cardiovascular disease. , 2011, Journal of the American College of Cardiology.
[9] W. Cushman,et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. , 2012, Kidney international.
[10] A. Jaffe,et al. Analytical validation of a high-sensitivity cardiac troponin T assay. , 2010, Clinical chemistry.
[11] Anushka Patel,et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.
[12] Mark Woodward,et al. The Relative and Combined Ability of High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Cardiovascular Events and Death in Patients With Type 2 Diabetes , 2013, Diabetes Care.
[13] F. Crea,et al. Primary Coronary Microvascular Dysfunction: Clinical Presentation, Pathophysiology, and Management , 2010, Circulation.
[14] V. Gudnason,et al. N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS , 2012, European heart journal.
[15] A. Urbani,et al. Proteomics and nephrology. , 2012, Journal of nephrology.
[16] D. de Zeeuw,et al. High-sensitivity troponin T predicts worsening of albuminuria in hypertension; results of a nested case–control study with confirmation in diabetes , 2013, Journal of hypertension.
[17] D. Levy,et al. Prognostic Utility of Novel Biomarkers of Cardiovascular Stress: The Framingham Heart Study , 2012, Circulation.
[18] M. Schocke,et al. Late microvascular obstruction after acute myocardial infarction: relation with cardiac and inflammatory markers. , 2012, International journal of cardiology.
[19] Simon Davies,et al. Epidemiology: Study Design and Data Analysis , 2006 .
[20] R. Rosenson,et al. Does microvascular disease predict macrovascular events in type 2 diabetes? , 2011, Atherosclerosis.
[21] S. de Servi,et al. NT pro-B-type natriuretic peptide levels are related to microvascular reperfusion in patients undergoing direct percutaneous transluminal coronary angioplasty for anterior ST-segment elevation myocardial infarction , 2010, Journal of cardiovascular medicine.
[22] Harald Sourij,et al. Multicentric Validation of Proteomic Biomarkers in Urine Specific for Diabetic Nephropathy , 2010, PloS one.
[23] M. Woodward,et al. Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes , 2009, Diabetes Care.
[24] J. Cristol,et al. Implications of adjustment of high-sensitivity cardiac troponin T assay. , 2013, Clinical chemistry.
[25] J. Kaski,et al. Coronary microvascular dysfunction in the clinical setting: from mystery to reality. , 2012, European heart journal.
[26] J. Chalmers. Resting heart rate and the risk of microvascular complications in patients with type 2 diabetes , 2012 .
[27] Ewout W Steyerberg,et al. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.
[28] M. Laakso. Heart in Diabetes: A Microvascular Disease , 2011, Diabetes Care.
[29] S. Schinner. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .
[30] D. Atar,et al. Relation of cardiac troponin I and microvascular obstruction following ST-elevation myocardial infarction , 2011, Acute cardiac care.
[31] M. Woodward,et al. Resting Heart Rate and the Risk of Microvascular Complications in Patients With Type 2 Diabetes Mellitus , 2012, Journal of the American Heart Association.
[32] G. Navis,et al. Copeptin, a Surrogate Marker for Arginine Vasopressin, , 2013 .
[33] Roger Newson,et al. Comparing the Predictive Powers of Survival Models Using Harrell's C or Somers’ D , 2010 .
[34] A. Lavoinne,et al. Two-year stability of NT-proBNP in frozen samples using the Roche Elecsys system , 2008, Annals of clinical biochemistry.
[35] J. Griffith,et al. Cardiovascular disease and subsequent kidney disease. , 2007, Archives of internal medicine.
[36] J. McMurray,et al. A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. , 2011, American heart journal.
[37] A. Sharrett,et al. Sources of variability in measurements of cardiac troponin T in a community-based sample: the atherosclerosis risk in communities study. , 2011, Clinical chemistry.
[38] Atsushi Araki,et al. Predicting Macro- and Microvascular Complications in Type 2 Diabetes , 2013, Diabetes Care.
[39] Diederick Grobbee,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.